Share this article and save a life!
What if you could run your clinical trial before running your clinical trial?
Pharma CMOs and clinical development leads: that question should stop you cold.
More than 90% of drugs that enter clinical trials fail. Three out of four of those failures come down to efficacy and safety, meaning the drug just did not work or was not safe. And by the time you find out, you have already burned years and hundreds of millions of dollars.
QuantHealth just raised $45M in Series B funding to change that math. 🧬
Here is who they are and what they built.
Founded in 2020 by CEO Orr Inbar and Chief Strategy and Operations Officer Arnon Horev, QuantHealth built an AI platform that simulates clinical trials before they happen. Instead of enrolling patients and waiting years for data, their platform models how a specific trial design would likely play out, testing different protocols, flagging efficacy and safety risks, and optimizing the design before a dollar is committed to a real study.
As Inbar put it directly: “Today, decisions are still made through real-world iteration. We’re fundamentally changing that model.”
🔹 Round: $45M Series B, closed August 4, 2026
🔹 Total raised: $75M since founding in 2020
🔹 Lead investor: Qumra Capital
🔹 Participating investors: Sanofi Ventures, Pitango HealthTech, Bertelsmann Healthcare Investments, Accenture Ventures, Artofin Venture Capital Fund L.P., GC Ventures, NewHealth Ventures, Shoni Top Ventures, and Esplanade Ventures
The traction is already real, according to Ventureburn. QuantHealth has simulated more than 600 clinical trials across 30 medical indications. Claimed predictive accuracy is up to 90%. And 12 of the world’s top 20 pharmaceutical companies are already using the platform.
That last number matters more than any other.
💡 The new capital goes into three areas worth tracking:
🔹 Next-generation AI models with larger datasets to sharpen simulation accuracy
🔹 Expanding disease coverage from 30 to 40-plus indications, with a focus on oncology, cardiometabolic, and inflammatory diseases
🔹 Extending beyond trial design into commercial planning, moving the platform from lab all the way to launch
Bookmark this if you work in clinical development, pharma strategy, or health tech investing. The shift from real-world iteration to simulation-first development is accelerating, and this round is evidence.
Here is what strikes me as a founder.
The investor mix tells the real story. When Sanofi Ventures and Accenture Ventures are both in the cap table alongside financial VCs, you are not looking at speculative AI. You are looking at a platform that large incumbents believe will be embedded in how they work. Strategic investors do not write checks on hypotheticals. They write checks on things they intend to use.
QuantHealth operates out of Tel Aviv and New York with about 85 people. They are still small enough to move fast and already big enough to be inside the workflows of the companies that decide which drugs reach patients.
The clinical trial machine has run roughly the same way for decades. The real cost of that model is not just money. It is time, and patients waiting for drugs that fail in year three of a trial that better data might have stopped in year one.
Simulation-first clinical development is not a feature upgrade. It is a different model entirely. Whether this one delivers on its 90% accuracy claim at scale is the real test, but the direction is right.
👉 Follow Jonathan Govette, CEO of Oatmeal Health, for daily healthcare insights on LinkedIn. Deeper dives in The Oatmeal Bite on Substack: https://news.oatmealhealth.com
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
